Please select the option that best describes you:
How do you counsel patients on safety and toxicity of delgocitinib?
Are there patients in whom you would not offer this due to safety concerns? How do you explain to patients that topical JAK inhibitors carry a different risk profile than systemic JAK inhibitors?
Answer from: at Academic Institution
I can't think of any situation, except maybe an active ongoing skin infection, in which I'd be hesitant to offer Anzupgo.
I do bring up that they are going to get information from the pharmacy that mentions some scary-sounding things that may be a risk with related medications taken as a pill, but ...
Sign In or Register to read more
Answer from: at Academic Institution
I request all eligible patients to complete the vaccines for herpes zoster prior to starting.
Delgocitinib has been reported to cause neutropenia, suggesting there is systemic absorption, so I do not recommend it for patients with a history of VTE.
I rarely see highly immunosuppressed patients wit...